Research in CRISPR based epigenome editing is still in its early stages, particularly in the context of pediatrics. Preclinical studies have shown promising results in animal models, but more research is needed to translate these findings into clinical applications. Ongoing studies are focused on improving delivery mechanisms, enhancing specificity, and ensuring safety.
